See more : JAPAN MATERIAL Co., Ltd. (6055.T) Income Statement Analysis – Financial Results
Complete financial analysis of Windlas Biotech Limited (WINDLAS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Windlas Biotech Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Warner Music Group Corp. (WMG) Income Statement Analysis – Financial Results
- Zumtobel Group AG (ZMTBY) Income Statement Analysis – Financial Results
- United Maritime Corporation (USEA) Income Statement Analysis – Financial Results
- Apex Medical Corp. (4106.TW) Income Statement Analysis – Financial Results
- Aida Pharmaceuticals, Inc. (AIDA) Income Statement Analysis – Financial Results
Windlas Biotech Limited (WINDLAS.BO)
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO services, including product discovery, product development, licensing, and commercial manufacturing of generic products. It manufactures nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and chewable or dispersible. The company was incorporated in 2001 and is based in Gurugram, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 6.31B | 5.11B | 4.63B | 4.27B | 3.28B | 3.05B | 3.52B |
Cost of Revenue | 4.00B | 3.25B | 3.03B | 2.74B | 2.12B | 1.92B | 3.09B |
Gross Profit | 2.31B | 1.85B | 1.61B | 1.52B | 1.17B | 1.13B | 432.84M |
Gross Profit Ratio | 36.54% | 36.26% | 34.65% | 35.69% | 35.57% | 37.13% | 12.30% |
Research & Development | 78.77M | 89.48M | 65.11M | 36.06M | 38.74M | 41.87M | 19.58M |
General & Administrative | 879.42M | 40.12M | 47.69M | 35.49M | 24.16M | 79.42M | 166.48M |
Selling & Marketing | 48.32M | 146.00M | 106.82M | 83.91M | 87.93M | 53.18M | 3.43M |
SG&A | 927.74M | 186.12M | 154.51M | 119.40M | 112.09M | 132.60M | 169.91M |
Other Expenses | 0.00 | 4.35M | 770.00K | 1.98M | 280.00K | 1.69M | -18.61M |
Operating Expenses | 1.01B | 1.37B | 1.20B | 1.08B | 843.15M | 830.32M | 208.10M |
Cost & Expenses | 5.01B | 4.63B | 4.23B | 3.82B | 2.96B | 2.75B | 3.30B |
Interest Income | 19.69M | 34.90M | 42.85M | 19.21M | 10.79M | 8.48M | 5.15M |
Interest Expense | 11.05M | 7.88M | 14.17M | 12.90M | 25.26M | 48.38M | 64.68M |
Depreciation & Amortization | 134.44M | 123.64M | 121.47M | 129.65M | 92.93M | 105.91M | 173.47M |
EBITDA | 916.40M | 701.91M | 591.29M | 361.68M | 439.53M | 923.11M | 435.41M |
EBITDA Ratio | 14.52% | 12.65% | 12.43% | 7.52% | 10.79% | 13.30% | 11.31% |
Operating Income | 1.30B | 481.40M | 397.48M | 435.98M | 325.06M | 282.05M | 224.74M |
Operating Income Ratio | 20.59% | 9.43% | 8.58% | 10.22% | 9.90% | 9.24% | 6.38% |
Total Other Income/Expenses | -527.98M | -438.32M | -403.00M | -218.58M | -78.50M | 458.10M | -27.48M |
Income Before Tax | 770.91M | 570.39M | 455.65M | 217.40M | 246.68M | 761.15M | 197.26M |
Income Before Tax Ratio | 12.22% | 11.17% | 9.83% | 5.09% | 7.51% | 24.93% | 5.60% |
Income Tax Expense | 189.04M | 144.13M | 74.76M | 61.70M | 84.55M | 122.93M | 86.52M |
Net Income | 581.87M | 426.26M | 380.89M | 158.32M | 162.13M | 638.22M | 111.98M |
Net Income Ratio | 9.22% | 8.35% | 8.22% | 3.71% | 4.94% | 20.91% | 3.18% |
EPS | 27.97 | 19.70 | 18.58 | 8.70 | 8.90 | 29.28 | 7.06 |
EPS Diluted | 27.88 | 19.70 | 18.58 | 8.70 | 8.90 | 29.28 | 6.80 |
Weighted Avg Shares Out | 20.80M | 21.64M | 20.50M | 18.21M | 18.21M | 21.79M | 15.87M |
Weighted Avg Shares Out (Dil) | 20.87M | 21.64M | 20.50M | 18.21M | 18.21M | 21.79M | 16.46M |
Source: https://incomestatements.info
Category: Stock Reports
What is Windlas Biotech’s return on equity?
Company has a low return on equity of 12.3% over last 3 years.
What is Windlas Biotech’s revenue growth trend?
Over the past 5 years, the revenue of WINDLAS BIOTECH has grown at a CAGR of 18.1%.